DistantNews
Support us
🇰🇷 South Korea /Health & Science

After Phase 3 Cancer Vaccine Success, Moderna Expands Into Standalone mRNA Treatments and In Vivo CAR-T

From Chosun Ilbo · () Korean

Translated from Korean and summarized by DistantNews. Read the original for the full story.

At a glance

News Sources not specified Outcome reported
  • Moderna is expanding its oncology pipeline after a personalized mRNA cancer vaccine succeeded in a Phase 3 trial.
  • The company is evaluating the possibility of using the vaccine alone, beyond combination treatment with immuno-oncology drugs.
  • Moderna also plans to research in vivo CAR-T therapies designed to target cancer cells inside the body after one injection.

Moderna is widening its ambitions in cancer treatment after the success of a Phase 3 trial for a personalized mRNA cancer vaccine. The company’s next steps could move beyond combining the vaccine with immuno-oncology drugs.

Moderna is expected to evaluate whether the cancer vaccine can work as a standalone treatment. It is also expanding its research into in vivo CAR-T, a technology intended to create cancer-fighting CAR-T cells inside the body and destroy cancer cells with a single injection.

About this summary

Originally published by Chosun Ilbo in Korean. Translated, summarized, and contextualized automatically by DistantNews, with a note on how the source frames the story. Not individually reviewed before publishing. How this works.

More Stories

From Our Blog